New Orleans—People with intractable angina received discouraging and encouraging news from researchers presenting data at the American College of Cardiology's annual meeting held here in early March.
In the headline-grabbing field of gene transfer, results of the first large, double-blind, placebo-controlled trial of therapeutic angiogenesis in patients with severe angina showed, essentially, that the therapy worked only as well as the placebo. While researchers presenting the data warned that their results are preliminary and insisted that it's too early to dismiss gene therapy as a treatment for angina, Genentech Inc, manufacturer of the tested recombinant human vascular endothelial growth factor (rhVEGF 165), called the results "disappointing."
Mitka M. High-Tech Angina Relief Explored in Treatment Trials. JAMA. 1999;281(14):1258-1260. doi:10.1001/jama.281.14.1258-JMN0414-2-1